[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585257":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":30,"responsibleParty":45,"collaborators":11,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":11,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":11,"enrollmentInfo":56,"targetDuration":11,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":11,"overallStatus":33,"whyStopped":11,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Shandong First Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention(CM336)","EXPERIMENTAL",null,[13],"Biological: CM336 Injection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"BIOLOGICAL","CM336 Injection","subcutaneous CM336 administration",[9],[21],{"name":22,"affiliation":23,"role":24},"Furen Zhang","Dermatology Hospital affiliated to Shandong First Medical University","PRINCIPAL_INVESTIGATOR",[26],{"name":22,"role":27,"phone":28,"phoneExt":11,"email":29},"CONTACT","15854179852","splcsy@126.com",[31],{"facility":32,"status":33,"city":34,"state":11,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Dermatology Hospital Affiliated to Shandong First Medical University","RECRUITING","Jinan","China","CN",{"type":38,"coordinates":39},"Point",[40,41],116.99722,36.66833,{"lat":41,"lon":40},[44],{"name":22,"role":27,"phone":28,"phoneExt":11,"email":11},{"type":46,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100585257","phase-2-a-study-to-evaluate-cm336-in-adults-with-autoimmune-bullous-disease-100585257",false,"NCT06900010","A Study to Evaluate CM336 in Adults With Autoimmune Bullous Disease","An Open-label, PhaseⅡ Study to Evaluate the Efficacy and Safety of CM336 (BCMA\u002FCD3 Bispecific Antibody) in Adults With Moderate to Severe Autoimmune Bullous Disease","Inclusion Criteria:\n\n* 1\\. Confirmed diagnosis of autoimmune bullous disease；\n* 2\\. Age ≥18 years, regardless of gender；\n* 3\\. Voluntarily signed informed consent form, with understanding of the study's nature, purpose, procedures, and willingness to comply with trial requirements.\n\nExclusion Criteria:\n\n* 1\\. History of clinically significant diseases that, in the investigator's judgment, may pose safety risks to the subject during participation；\n* 2\\. Prior treatment with anti-B-cell maturation antigen (BCMA) therapy；\n* 3\\. History of allergic reactions to humanized monoclonal antibodies or known allergy to any component of CM336；\n* 4\\. Any other condition deemed by the investigator to render the subject unsuitable for study participation.","ALL","18 Years",{"count":57,"type":58},30,"ESTIMATED","INTERVENTIONAL",[61],"PHASE2","to Evaluate the Efficacy and Safety of CM336 (BCMA\u002FCD3 Bispecific Antibody) in Adults with Moderate to Severe Autoimmune Bullous Disease",[64],"Autoimmune Bullous Disease","2026-03-31",{"date":67,"type":68},"2026-04-06","ACTUAL",{"date":70,"type":68},"2025-04-22",{"date":72,"type":58},"2028-01-01",{"name":5,"class":6},1]